Company Overview
About InpharmD
InpharmD is an Atlanta-based healthcare technology company providing AI-assisted drug information and clinical pharmacist intelligence to healthcare providers — enabling physicians, nurses, and clinical staff to get evidence-based answers to complex drug questions (drug interactions, off-label use guidance, dosing in special populations, emerging therapies) through an AI platform that combines clinical pharmacist review with database-backed pharmaceutical intelligence. Founded in 2018 and a Y Combinator W21 graduate, InpharmD raised $6.63 million total including a $6.5 million seed round in December 2023 led by 645 Ventures with participation from Qlarant Capital and Atlanta Ventures.
Business Model & Competitive Advantage
InpharmD's platform delivers AI-generated drug information responses that are reviewed and validated by clinical pharmacists before delivery, providing a higher standard of reliability than pure AI-generated responses for clinical decision support. Healthcare providers can query drug interactions for complex polypharmacy patients, dosing guidance for renal or hepatic impairment, and evidence reviews for emerging treatments where prescribing guidance is evolving rapidly. The pharmacist-in-the-loop review model addresses the reliability requirements for clinical AI tools where incorrect information can cause patient harm.
Competitive Landscape 2025–2026
In 2025, InpharmD competes in the clinical decision support and pharmacy intelligence market with Wolters Kluwer (UpToDate, the dominant clinical reference), Elsevier (Clinical Pharmacology), IBM Watson Health (legacy), and newer AI clinical assistants (Doximity AI, Glass Health) for healthcare provider drug information. Clinical pharmacist access is increasingly limited in many hospital systems — telepharmacy and centralized pharmacy models have reduced the availability of pharmacists for individual clinician questions. InpharmD's AI-assisted pharmacist service expands access to pharmaceutical expertise. The 645 Ventures and YC backing validates the healthcare AI market opportunity. The 2025 strategy focuses on hospital system and health system enterprise deployments, expanding the AI model's pharmaceutical knowledge base, and building the formulary and insurance coverage intelligence that completes the prescribing decision context.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
InpharmD is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Cursor
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities dir
Kindful
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid
Compare InpharmD with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from InpharmD? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim InpharmD Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention InpharmD vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →